CRISPR Therapeutics AG’s recent filing unveils that its Chief Medical Officer Patel Naimish unloaded Company’s shares for reported $0.14 million on May 29 ’25. In the deal valued at $35.94 per share,3,932 shares were sold. As a result of this transaction, Patel Naimish now holds 6,068 shares worth roughly $0.22 million.
Then, Kulkarni Samarth sold 10,031 shares, generating $413,578 in total proceeds. Upon selling the shares at $41.23, the Chief Executive Officer now owns 195,085 shares.
Before that, Bruno Julianne sold 1,714 shares. CRISPR Therapeutics AG shares valued at $70,668 were divested by the Chief Operating Officer at a price of $41.23 per share. As a result of the transaction, Bruno Julianne now holds 10,544 shares, worth roughly $0.39 million.
Evercore ISI upgraded its CRISPR Therapeutics AG [CRSP] rating to an Outperform from a an In-line in a research note published on February 14, 2025; the price target was increased to $99 from $60. A number of analysts have revised their coverage, including TD Cowen’s analysts, who increased its forecast for the stock in mid February from “a Sell” to “a Hold”. H.C. Wainwright began covering CRSP with “Buy” recommendation on February 03, 2025. Needham maintained its rating on August 06, 2024. It rated CRSP as “a Buy”.
Price Performance Review of CRSP
On Monday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock jump 1.82% to $36.95. Over the last five days, the stock has gained 0.24%. CRISPR Therapeutics AG shares have fallen nearly -6.12% since the year began. Nevertheless, the stocks have fallen -31.38% over the past one year. While a 52-week high of $67.88 was reached on 02/19/25, a 52-week low of $30.04 was recorded on 04/07/25. SMA at 50 days reached $37.01, while 200 days put it at $43.54.
Levels Of Support And Resistance For CRSP Stock
The 24-hour chart illustrates a support level at 36.22, which if violated will result in even more drops to 35.49. On the upside, there is a resistance level at 38.01. A further resistance level may holdings at 39.07. The Relative Strength Index (RSI) on the 14-day chart is 48.80, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.61, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 61.48%. Stochastics %K at 33.40% indicates the stock is a holding.
The most recent change occurred on August 02, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $90 price target.
